Helixgate

Helixgate

Uncategorized

Former FDA leaders, pharma speak out on mifepristone

After issuing a week-long pause on a federal appeals court decision to stop mail orders of the abortion medication mifepristone, the Supreme Court is expected to take further steps in the case by the end of the day Monday. How the court moves forward could have a major impact on the regulatory authority of the Food and Drug Administration as well as on abortion providers and patients.

“The fundamental question is: Who gets to regulate mifepristone?” said Laurie Sobel, an associate director for women’s health policy at KFF. “Can a state go further than the FDA? Is the FDA the floor or the ceiling?”

Read the rest…

Read More

Published

on

After issuing a week-long pause on a federal appeals court decision to stop mail orders of the abortion medication mifepristone, the Supreme Court is expected to take further steps in the case by the end of the day Monday. How the court moves forward could have a major impact on the regulatory authority of the Food and Drug Administration as well as on abortion providers and patients.

“The fundamental question is: Who gets to regulate mifepristone?” said Laurie Sobel, an associate director for women’s health policy at KFF. “Can a state go further than the FDA? Is the FDA the floor or the ceiling?”

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Remembering J. Craig Venter, PhD

Published

on

J. Craig Venter, PhD recently passed away at the age of 79 from complications following a cancer diagnosis. He was well known in both science and industry and was an integral part of sequencing the human genome in the late 90s, competing with the government organized Human Genome Project. Throughout his career, he made many other important contributions in microbiology, with the “minimal cell,” in synthetic biology, and in personalized medicine. GEN editors share anecdotes of their experiences with him, reflect on the impact that his work has had on various fields in biology, in biotech, and in how the world has responded to the disruptions caused by Venter.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Genomics Pioneer and Life Sciences Entrepreneur J. Craig Venter Dies at 79
GEN, April 30, 2026

J. Craig Venter Describes a Human Genomics Revolution Still In Progress
By J. Craig Venter, PhD, GEN, June 13, 2025

Lessons from the Minimal Cell
By Hana El-Samad, PhD, GEN, August 21, 2023

From Sequencing to Sailing: Three Decades of Adventure with Craig Venter
By Fay Lin, PhD, GEN, March 8, 2023

Cracking the Genome
By Kevin Davies, PhD

Touching Base Podcast
Hosted by Corinna Singleman, PhD

Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD

The post Remembering J. Craig Venter, PhD appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Uncategorized

Opinion: I’m fighting misinformation online. False hantavirus claims follow a now-familiar playbook

I learned about hantavirus misinformation this week in the same way I now learn about most public health misinformation: My followers sent it to me.

Within hours of the first headlines about a hantavirus outbreak linked to the expedition cruise ship MV Hondius, my DMs started filling with screenshots. One was from the account of a Texas doctor who became well known during Covid for promoting ivermectin. She was already telling followers that ivermectin would work against hantavirus, too.

Read the rest…

Read More

Published

on

I learned about hantavirus misinformation this week in the same way I now learn about most public health misinformation: My followers sent it to me.

Within hours of the first headlines about a hantavirus outbreak linked to the expedition cruise ship MV Hondius, my DMs started filling with screenshots. One was from the account of a Texas doctor who became well known during Covid for promoting ivermectin. She was already telling followers that ivermectin would work against hantavirus, too.

Read the rest…

Read More

Continue Reading

Uncategorized

FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering

Published

on

🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said. The agency asked for more information from …

Continue Reading
Advertisement

Trending